Amylyx Pharmaceuticals Inc - Asset Resilience Ratio
Amylyx Pharmaceuticals Inc (AMLX) has an Asset Resilience Ratio of 27.15% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Amylyx Pharmaceuticals Inc (AMLX) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Amylyx Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See AMLX book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Amylyx Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AMLX market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $90.33 Million | 27.15% |
| Total Liquid Assets | $90.33 Million | 27.15% |
Asset Resilience Insights
- Very High Liquidity: Amylyx Pharmaceuticals Inc maintains exceptional liquid asset reserves at 27.15% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Amylyx Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Amylyx Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910 |
Drug Manufacturers - Specialty & Generic | 11.95% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 16.92% |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999 |
Drug Manufacturers - Specialty & Generic | 5.22% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332 |
Drug Manufacturers - Specialty & Generic | 6.02% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Hainan Honz Pharmaceutical Co
SHE:300086 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
Annual Asset Resilience Ratio for Amylyx Pharmaceuticals Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Amylyx Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 27.15% | $90.33 Million | $332.64 Million | -24.03pp |
| 2024-12-31 | 51.18% | $99.11 Million | $193.63 Million | +12.31pp |
| 2023-12-31 | 38.88% | $201.16 Million | $517.45 Million | -33.78pp |
| 2022-12-31 | 72.66% | $284.42 Million | $391.45 Million | +29.17pp |
| 2021-12-31 | 43.49% | $45.93 Million | $105.61 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $14.10 Million | -- |
About Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and… Read more